The primary goal of systemic oral enzyme therapy (SET) administration is to influence the course of inflammatory process. Its efficacy has been proven in a series of randomized double blind controlled clinical trials. Growing positive experience of paediatric practitioners regarding the effect of SET in the complex treatment of children with recurrent respiratory inflammations (RZDC) was the main suggestion for performance of retrospective multicentric evaluation of the preparationWobenzym, comparing its efficacy with that of bacterial immunomodulators (BIM). Medical records of 468 children at the age of 3-18 years (SET: n=346 children; BIM: n=122 children) were analyzed at 14 workplaces of paediatric practitioners. Number of respiratory inflammations (inflammations of upper and lower respiratory tract including sinusitis and otitis media according to MKN-10) as well as number of interrelated antibiotic cures in the period of 12months before and after beginning of the therapy under investigation were followed. Data obtained were processed by means of the PATS® system (Patient Analysis&Tracking System). In order to evaluate the decrease rate of number of diseases and number of interrelated antibiotic cures, the authors used the ,,index of change" [I (%)]. The results were compared using Student's t-test. A statistically significant decrease of both investigated parameters was observed in both groups. In the SET group, there was a decrease in the average number of respiratory inflammations from 5.3 to 2.2 (IRZDC = _59%, p.001), while in the BIM group there was a decrease from 5.2 to 3.4 (IRZDC = _32%, p.001). The average number of interrelated antibiotic cures decreased in the SET group from 2.7 to 0.8 (IATB = _68%, p.001) and from 2.7 to 1.5 (IATB = _35%, p.001) in the BIM group. In the SET group there were no statistically significant differences among IRZDC and IATB for age subgroups (3-6 years, 7-10 years and 11-18 years, respectively).

        Key words: systemic oral enzyme therapy, recurrent respiratory inflammations, post-registration retrospective multi-centric evaluation, bacterial immnunomodulators